
Q&A: Forbion Capital Partners' Sander Slootweg

Life-sciences-focused venture firm Forbion Capital Partners recently held a €360m final close for its fourth flagship fund, surpassing its initial hard-cap of €350m. Managing partner Sander Slootweg speaks to Francesca Veronesi about the fundraising process, the firm's 'build' strategy and the European life sciences venture market
Latest News
CVC acquires Scan Global logistics from AEA Investors
AEA and management have reinvested for a minority stake in the Danish logistics provider
Eurazeo shakes up executive board; CEO Virginie Morgon to depart
New board members are chairmen Christophe Bavière and William Kadouch-Chassaing, as well as Sophie Flak and Olivier Millet
Seventure preps third generation of microbiome fund
Health for Life III to be slightly larger than EUR 250m predecessor; will invest in Europe, US, Israel
Idacapital targets close to USD 30m for impact fund
Turkish VC seeks to raise USD 5m every six months for new rolling investment vehicle